Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
PD-L1
Adult
Male
0301 basic medicine
Cancer Research
Adolescent
Immunology
Bone Neoplasms
B7-H1 Antigen
Young Adult
03 medical and health sciences
Lymphocytes, Tumor-Infiltrating
0302 clinical medicine
Biomarkers, Tumor
Immunology and Allergy
Humans
Neoplasm Metastasis
Child
Aged
Osteosarcoma
Tumour-infiltrating lymphocytes
Histocompatibility Antigens Class I
HLA class I
Middle Aged
Prognosis
3. Good health
Oncology
Original Article
Female
Immunotherapy
DOI:
10.1007/s00262-016-1925-3
Publication Date:
2016-11-17T01:55:30Z
AUTHORS (6)
ABSTRACT
Immunotherapy may be an excellent choice for treating osteosarcoma given its exceptionally high genomic instability, potentially generating neoantigens. In this study, we aim to investigate the HLA class I expression, PD-L1 and tumour-infiltrating lymphocytes in primary osteosarcomas relapses/metastases, as well their changes during disease progression. Tumour samples from multiple stages of (pretreatment biopsies, surgical resections osteosarcomas, relapses metastases) were collected stained HLA-A (HCA2), HLA-B/C (HC10), β2-microglobulin using immunohistochemistry on whole sections. Density type T-cell infiltrate characterised by a triple immunofluorescent staining CD3-CD8-FOXP3. Overall, 85 formalin-fixed, paraffin-embedded blocks 25 patients included. expression was detected 94% (strongly positive 56%, heterogeneous 38%) negative or weakly 6%, without differences between disease. more frequently than HLA-B/C. Tumour-infiltrating highly mainly observed tumour areas with I. T cells significantly higher metastases tumours local (p = 0.0003). Positive found 13% tumours, 25% 48% correlated 0.002). An increased number compared suggesting accessibility cells, could imply that metastatic benefit T-cell-based immunotherapy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (32)
CITATIONS (90)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....